Free Trial
→ Why Elon put $51 million into this (From True Market Insiders) (Ad) Buy VRDN Stock  Free VRDN Stock Alerts

Viridian Therapeutics (VRDN) Financials

Viridian Therapeutics logo
$12.80 -0.50 (-3.76%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$12.79 -0.01 (-0.08%)
As of 04/15/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Viridian Therapeutics

Annual Income Statements for Viridian Therapeutics

This table shows Viridian Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -7.89 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270
Consolidated Net Income / (Loss)		 -7.89 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270
Net Income / (Loss) Continuing Operations		 -7.89 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270
Total Pre-Tax Income 		-7.89 -11 -17 -27 -34 -43 -111 -79 -130 -238 -270
Total Operating Income		 -6.87 -11 -17 -27 -33 -42 -110 -80 -134 -254 -299
Total Gross Profit		 0.95 0.07 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30
Total Revenue		 4.32 2.54 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30
Operating Revenue		 4.32 2.54 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30
Total Cost of Revenue		 3.37 2.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.82 11 20 31 41 46 111 83 136 255 299
Selling, General & Admin Expense		 6.86 7.69 6.77 11 11 12 13 26 35 95 61
Research & Development Expense		 0.35 1.00 14 20 30 35 98 57 101 160 238
Total Other Income / (Expense), net		 -1.02 -0.14 -0.33 -0.38 -0.87 -0.84 -0.51 0.32 4.43 17 29
Interest Expense		 1.02 0.14 0.33 0.38 0.87 0.84 0.51 0.00 0.49 1.85 3.05
Interest & Investment Income		 - - - - - - - 0.32 4.92 19 32
Basic Earnings per Share		 ($3.50) ($21.02) ($28.21) ($1.38) ($1.10) ($20.04) ($31.13) ($6.66) ($364.59) ($525.30) ($412.71)
Weighted Average Basic Shares Outstanding		 2.26M 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 11.92M 32.32M 45.00M 68.19M
Diluted Earnings per Share		 ($3.50) ($21.02) ($28.21) ($1.38) ($1.10) ($20.04) ($31.13) ($6.66) ($364.59) ($525.30) ($412.71)
Weighted Average Diluted Shares Outstanding		 2.26M 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 11.92M 32.32M 45.00M 68.19M
Weighted Average Basic & Diluted Shares Outstanding		 2.26M 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 25.91M 42.90M 62.77M 81.48M

Quarterly Income Statements for Viridian Therapeutics

This table shows Viridian Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Consolidated Net Income / (Loss)		 -29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Net Income / (Loss) Continuing Operations		 -29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Total Pre-Tax Income 		-29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Total Operating Income		 -30 -49 -72 -59 -51 -71 -56 -72 -83 -87
Total Gross Profit		 1.20 0.36 0.00 0.07 0.07 0.17 0.00 0.07 0.09 0.14
Total Revenue		 1.20 0.36 0.00 0.07 0.07 0.17 0.00 0.07 0.09 0.14
Total Operating Expenses		 31 49 73 59 51 72 56 72 84 88
Selling, General & Admin Expense		 8.86 9.85 22 19 21 33 15 16 14 16
Research & Development Expense		 22 39 51 40 30 39 41 56 69 72
Total Other Income / (Expense), net		 0.88 3.28 4.32 4.21 3.56 4.62 7.36 7.19 6.79 7.75
Interest Expense		 0.16 0.17 0.17 0.17 0.60 0.92 0.59 0.60 1.00 0.86
Interest & Investment Income		 1.04 3.45 4.49 4.38 4.16 5.53 7.94 7.79 7.80 8.60
Basic Earnings per Share		 ($0.86) ($1.42) ($1.61) ($1.27) ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75)
Weighted Average Basic Shares Outstanding		 33.74M 32.32M 42.24M 43.25M 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M
Diluted Earnings per Share		 ($0.86) ($1.42) ($1.61) ($1.27) ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75)
Weighted Average Diluted Shares Outstanding		 33.74M 32.32M 42.24M 43.25M 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M
Weighted Average Basic & Diluted Shares Outstanding		 40.25M 42.90M 43.13M 43.67M 52.59M 62.77M 63.82M 63.89M 79.21M 81.48M

Annual Cash Flow Statements for Viridian Therapeutics

This table details how cash moves in and out of Viridian Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 4.91 5.71 0.87 25 -15 -7.76 21 -3.60 113 -53 -3.23
Net Cash From Operating Activities		 -2.21 -6.90 -15 -28 -27 -36 -30 -55 -94 -184 -232
Net Cash From Continuing Operating Activities		 -2.21 -6.90 -15 -28 -27 -36 -30 -55 -94 -184 -232
Net Income / (Loss) Continuing Operations		 -7.89 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270
Consolidated Net Income / (Loss)		 -7.89 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270
Depreciation Expense		 0.14 0.18 0.30 0.30 0.28 0.29 0.24 0.12 0.26 0.52 0.54
Amortization Expense		 - - - 0.00 -0.42 -0.43 0.34 1.05 0.02 -11 -15
Non-Cash Adjustments To Reconcile Net Income		 4.88 2.90 0.64 2.50 4.05 4.31 76 21 20 74 43
Changes in Operating Assets and Liabilities, net		 0.66 1.35 1.54 -4.47 1.94 1.65 4.43 2.18 16 -9.43 9.50
Net Cash From Investing Activities		 -0.27 -0.10 -0.25 1.03 -30 28 -50 -74 -115 -94 -229
Net Cash From Continuing Investing Activities		 -0.27 -0.10 -0.25 1.03 -30 28 -50 -74 -115 -94 -229
Purchase of Property, Plant & Equipment		 -0.27 -0.12 -0.25 -0.25 -0.45 -0.08 -0.04 -0.34 -0.80 -0.90 -0.51
Purchase of Investments		 - - -1.00 0.00 -62 -33 -82 -188 -223 -408 -695
Sale and/or Maturity of Investments		 - - 1.00 0.00 33 61 2.00 114 109 315 467
Net Cash From Financing Activities		 7.40 13 16 52 42 0.07 101 125 322 226 458
Net Cash From Continuing Financing Activities		 7.40 13 16 52 42 0.07 101 125 322 226 458
Repayment of Debt		 -0.04 -0.08 -0.34 -4.67 0.00 -2.33 -10 0.00 -0.45 -0.51 0.00
Repurchase of Common Equity		 - 0.00 - -1.85 -3.04 -0.08 -6.18 -8.28 -22 -12 -27
Issuance of Debt		 0.80 0.05 0.00 10 0.24 0.00 1.73 0.00 5.00 15 0.00
Issuance of Preferred Equity		 - - 16 - - 0.00 91 17 44 0.00 25
Issuance of Common Equity		 6.64 13 - 49 45 2.48 25 114 293 204 454
Other Financing Activities, net		 0.00 -0.36 0.20 0.30 0.18 0.00 -0.04 2.31 2.76 19 5.34
Other Net Changes in Cash		 - - - - - - - 0.00 0.00 - 0.00
Cash Interest Paid		 0.00 0.01 0.16 0.45 0.49 0.51 0.27 0.00 0.29 0.89 1.82

Quarterly Cash Flow Statements for Viridian Therapeutics

This table details how cash moves in and out of Viridian Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 313 -189 -67 -1.43 25 -8.77 -11 16 93 -101
Net Cash From Operating Activities		 -21 -34 -62 -45 -39 -38 -45 -46 -68 -73
Net Cash From Continuing Operating Activities		 -21 -34 -62 -45 -39 -37 -45 -46 -68 -73
Net Income / (Loss) Continuing Operations		 -29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Consolidated Net Income / (Loss)		 -29 -46 -68 -55 -48 -67 -49 -65 -77 -80
Depreciation Expense		 0.06 0.10 0.11 0.13 0.14 0.15 0.15 0.14 0.13 0.12
Amortization Expense		 0.24 -0.81 -2.92 -2.86 -2.45 -2.94 -4.54 -4.29 -3.31 -3.15
Non-Cash Adjustments To Reconcile Net Income		 5.27 5.53 15 17 15 27 13 12 9.18 8.97
Changes in Operating Assets and Liabilities, net		 2.62 6.96 -6.24 -4.72 -4.08 5.62 -4.96 11 2.98 0.45
Net Cash From Investing Activities		 43 -181 -13 41 48 -170 -143 62 -85 -63
Net Cash From Continuing Investing Activities		 43 -181 -13 41 48 -170 -143 62 -85 -63
Purchase of Property, Plant & Equipment		 -0.14 -0.19 -0.12 -0.33 -0.40 -0.05 0.00 -0.10 -0.29 -0.11
Purchase of Investments		 - -218 -77 -8.06 -50 -272 -226 -59 -228 -182
Sale and/or Maturity of Investments		 43 38 64 49 98 103 83 121 144 119
Net Cash From Financing Activities		 291 26 8.20 3.07 15 199 177 0.11 245 36
Net Cash From Continuing Financing Activities		 291 26 8.20 3.07 15 199 177 0.11 245 36
Repurchase of Common Equity		 - -0.93 0.00 - - -12 -10 -0.10 -15 -1.31
Issuance of Common Equity		 268 25 1.27 0.94 0.26 201 187 - 234 34
Other Financing Activities, net		 0.24 1.85 6.94 2.13 0.71 9.48 0.84 0.21 1.11 3.19
Cash Interest Paid		 - 0.15 0.11 0.11 0.21 0.45 0.45 0.46 0.46 0.45

Annual Balance Sheets for Viridian Therapeutics

This table presents Viridian Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 8.09 13 25 52 66 30 131 204 435 490 742
Total Current Assets		 6.79 12 24 52 65 30 130 200 431 486 738
Cash & Equivalents		 5.12 11 22 47 33 25 46 42 156 103 100
Short-Term Investments		 - - - 0.00 30 2.00 82 155 269 375 618
Accounts Receivable		 1.09 0.39 0.02 1.46 0.02 - 0.00 - 0.10 0.10 0.00
Prepaid Expenses		 0.40 0.32 1.75 2.97 2.87 2.89 1.97 2.75 6.52 9.01 21
Plant, Property, & Equipment, net		 1.21 1.15 0.63 0.56 0.73 0.52 0.31 0.38 1.33 1.67 1.24
Total Noncurrent Assets		 0.09 0.02 0.26 0.05 0.05 0.00 1.34 3.17 2.59 2.27 2.71
Other Noncurrent Operating Assets		 0.09 0.02 0.26 0.05 0.05 0.00 1.34 3.17 2.59 2.27 2.71
Total Liabilities & Shareholders' Equity		 8.09 13 25 52 66 30 131 204 435 490 742
Total Liabilities		 2.10 2.49 9.71 14 15 15 11 16 40 48 71
Total Current Liabilities		 1.99 2.47 6.89 3.90 6.73 10 11 14 33 27 48
Accounts Payable		 1.30 0.24 1.01 0.91 0.57 1.10 0.67 2.33 14 2.24 2.14
Accrued Expenses		 0.36 1.02 3.91 2.99 3.87 5.11 9.70 11 19 24 45
Current Deferred Revenue		 - - - - - 0.00 0.30 0.29 0.29 0.29 0.29
Total Noncurrent Liabilities		 0.11 0.02 2.82 10 8.07 4.33 0.54 2.36 6.68 22 23
Long-Term Debt		 - - 2.82 9.92 8.00 4.33 - - 4.65 20 21
Noncurrent Deferred Revenue		 - - - - - - - 1.15 0.86 0.57 0.28
Other Noncurrent Operating Liabilities		 0.11 0.02 0.00 0.15 0.07 0.00 0.54 1.21 1.17 0.99 2.02
Commitments & Contingencies		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.99 10 -62 39 51 16 120 188 395 442 672
Total Preferred & Common Equity		 5.99 10 -62 39 51 16 120 188 395 442 672
Preferred Stock		 0.00 0.00 - - - 0.00 181 134 142 207 189
Total Common Equity		 5.99 10 -62 39 51 16 -61 54 253 236 483
Common Stock		 13 28 5.16 132 178 184 218 412 741 961 1,479
Retained Earnings		 -6.64 -18 -67 -94 -126 -168 -279 -358 -488 -726 -996
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.00 0.00 -0.01 -0.16 -0.39 0.34 -0.01

Quarterly Balance Sheets for Viridian Therapeutics

This table presents Viridian Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 441 387 351 329 630 586 772
Total Current Assets		 437 383 346 324 627 582 767
Cash & Equivalents		 344 89 87 112 92 108 200
Short-Term Investments		 87 285 247 201 522 464 553
Accounts Receivable		 0.40 0.13 0.10 0.10 0.10 0.00 0.01
Prepaid Expenses		 5.64 8.62 12 11 14 10 14
Plant, Property, & Equipment, net		 0.83 1.59 1.88 1.80 1.53 1.51 1.29
Total Noncurrent Assets		 2.40 2.45 3.25 3.12 2.04 2.49 3.25
Other Noncurrent Operating Assets		 2.40 2.45 3.25 3.12 2.04 2.49 3.25
Total Liabilities & Shareholders' Equity		 441 387 351 329 630 586 772
Total Liabilities		 32 36 36 45 48 56 64
Total Current Liabilities		 25 30 29 23 26 37 41
Accounts Payable		 12 7.87 4.13 3.74 2.68 3.14 6.34
Accrued Expenses		 13 21 24 19 23 30 35
Current Deferred Revenue		 0.29 0.29 0.29 0.29 0.29 0.29 0.29
Total Noncurrent Liabilities		 6.36 6.51 6.95 22 22 20 23
Long-Term Debt		 4.61 4.68 4.71 20 20 17 21
Noncurrent Deferred Revenue		 0.93 0.79 0.72 0.65 0.50 0.43 0.36
Other Noncurrent Operating Liabilities		 0.81 1.04 1.53 1.29 0.90 1.65 2.16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 409 351 316 284 583 529 707
Total Preferred & Common Equity		 409 351 316 284 583 529 707
Preferred Stock		 142 135 135 135 200 200 189
Total Common Equity		 267 216 181 149 383 330 519
Common Stock		 710 772 793 808 1,158 1,170 1,434
Retained Earnings		 -442 -556 -611 -659 -774 -839 -916
Accumulated Other Comprehensive Income / (Loss)		 -0.94 -0.17 -0.17 -0.06 -0.37 -0.54 0.93

Annual Metrics and Ratios for Viridian Therapeutics

This table displays calculated financial ratios and metrics derived from Viridian Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.09% -41.25% 37.00% 15.13% 109.49% -46.80% -76.46% 182.19% -40.20% -82.28% -3.82%
EBITDA Growth		 -13,620.41% -63.66% -51.66% -57.20% -26.64% -26.80% -160.67% 28.46% -70.62% -97.79% -18.36%
EBIT Growth		 -3,385.79% -62.91% -51.85% -56.19% -24.69% -26.89% -162.94% 27.77% -68.45% -89.46% -17.52%
NOPAT Growth		 -3,385.79% -62.91% -51.85% -56.19% -24.69% -26.89% -162.94% 27.77% -68.45% -89.46% -17.52%
Net Income Growth		 -265.28% -43.57% -52.49% -53.48% -23.35% -28.04% -164.41% 28.27% -63.54% -83.05% -13.55%
EPS Growth		 71.38% -43.57% -34.21% 95.11% 20.29% -28.04% -55.34% 78.61% -5,374.32% -44.08% 21.43%
Operating Cash Flow Growth		 -89.47% -211.70% -113.90% -90.90% 4.70% -34.32% 17.41% -83.29% -71.92% -96.26% -26.14%
Free Cash Flow Firm Growth		 0.00% -111.69% -17.09% -143.89% 2.27% -28.64% -164.06% 25.24% -44.79% -139.49% -6.01%
Invested Capital Growth		 -57.85% -21.67% -430.89% 143.85% -184.66% -232.18% -172.77% -21.67% -168.58% 39.04% -67.49%
Revenue Q/Q Growth		 0.00% 0.16% -4.11% 20.57% -7.87% 9.96% -44.03% 5.71% 9.05% -37.82% 2,057.14%
EBITDA Q/Q Growth		 0.00% -6.71% -21.95% -1.42% -14.81% 1.28% -274.34% 44.02% -18.65% -10.18% -5.45%
EBIT Q/Q Growth		 0.00% -6.69% -21.08% -1.69% -14.14% 0.90% -269.75% 43.55% -17.48% -9.66% -5.65%
NOPAT Q/Q Growth		 0.00% -6.69% -21.08% -1.69% -14.14% 0.90% -269.75% 43.55% -17.48% -9.66% -5.65%
Net Income Q/Q Growth		 0.00% -6.81% -20.97% -1.58% -13.66% 0.47% -211.13% 41.49% -14.90% -9.73% -5.00%
EPS Q/Q Growth		 0.00% -6.81% -18.73% -14.05% -17.02% 0.47% -284.80% 47.27% -10,783.28% -10,490.73% -9,497.91%
Operating Cash Flow Q/Q Growth		 -40.62% -4.58% -15.57% -16.34% -3.60% 1.01% -5.79% -14.95% -22.94% -2.20% -17.94%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -3.48% -25.58% -0.93% 1.37% -227.36% 39.72% -9.61% -10.03% -9.19%
Invested Capital Q/Q Growth		 0.00% -57.68% -613.64% 322.20% -311.87% -93.81% -3,644.83% -0.30% -40.33% -60.57% -0.56%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 22.08% 2.60% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -155.63% -433.53% -479.93% -655.31% -396.12% -944.25% -10,457.52% -2,651.23% -7,563.83% -84,427.07% -103,898.34%
Operating Margin		 -158.96% -440.78% -488.55% -662.80% -394.51% -941.02% -10,512.38% -2,690.79% -7,579.23% -81,035.03% -99,018.21%
EBIT Margin		 -158.96% -440.78% -488.55% -662.80% -394.51% -941.02% -10,512.38% -2,690.79% -7,579.23% -81,035.03% -99,018.21%
Profit (Net Income) Margin		 -182.64% -446.34% -496.81% -662.30% -389.97% -938.65% -10,544.29% -2,680.16% -7,329.23% -75,711.47% -89,387.09%
Tax Burden Percent		 100.00% 100.00% 99.77% 98.50% 96.31% 97.80% 99.84% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 114.90% 101.26% 101.92% 101.44% 102.64% 101.99% 100.46% 99.60% 96.70% 93.43% 90.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -326.89% -1,007.19% 0.00% 0.00% -30,472.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -356.48% -960.08% 0.00% 0.00% -30,450.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 415.06% 869.05% 0.00% 0.00% 30,399.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 88.18% -138.14% -135.67% -98.99% -72.79% -124.81% -163.07% -51.61% -44.57% -56.80% -48.48%
Cash Return on Invested Capital (CROIC)		 -245.49% -982.88% 0.00% -2,202.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -116.77% -106.59% -90.21% -68.70% -55.78% -87.09% -136.68% -47.60% -42.05% -54.99% -48.51%
Return on Assets (ROA)		 -134.16% -107.93% -91.73% -68.65% -55.14% -86.87% -137.09% -47.42% -40.66% -51.37% -43.79%
Return on Common Equity (ROCE)		 88.18% -138.14% 274.43% 43.26% -72.79% -124.81% 54.05% 1.15% -23.46% -33.14% -31.27%
Return on Equity Simple (ROE_SIMPLE)		 -131.70% -108.82% 27.90% -68.84% -63.69% -265.79% -92.23% -42.30% -32.87% -53.78% -40.19%
Net Operating Profit after Tax (NOPAT)		 -4.81 -7.83 -12 -19 -23 -29 -77 -56 -94 -178 -209
NOPAT Margin		 -111.27% -308.55% -341.99% -463.96% -276.16% -658.72% -7,358.67% -1,883.55% -5,305.46% -56,724.52% -69,312.75%
Net Nonoperating Expense Percent (NNEP)		 29.59% -47.11% -39.81% -28.96% -21.28% -35.31% -45.76% -14.54% -11.63% -13.60% -10.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -23.52% -38.53% -30.24%
Cost of Revenue to Revenue		 77.92% 97.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 158.73% 303.07% 194.77% 272.60% 131.76% 261.06% 1,263.33% 870.91% 1,985.44% 30,254.46% 20,226.16%
R&D to Revenue		 8.03% 39.48% 393.79% 490.21% 362.76% 779.96% 9,349.05% 1,919.88% 5,693.79% 50,880.57% 78,892.05%
Operating Expenses to Revenue		 181.04% 443.38% 588.55% 762.80% 494.51% 1,041.02% 10,612.38% 2,790.79% 7,679.23% 81,135.03% 99,118.21%
Earnings before Interest and Taxes (EBIT)		 -6.87 -11 -17 -27 -33 -42 -110 -80 -134 -254 -299
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.72 -11 -17 -26 -33 -42 -110 -79 -134 -265 -314
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.76 0.00 6.04 1.82 0.97 0.00 7.97 4.65 4.86 3.15
Price to Tangible Book Value (P/TBV)		 0.00 0.76 0.00 6.04 1.82 0.97 0.00 7.97 4.65 4.86 3.15
Price to Revenue (P/Rev)		 0.00 3.13 1.04 58.13 11.14 3.42 61.27 144.94 663.46 3,647.53 5,028.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 196.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 18.20 48.76 4.92 0.00 111.90 123.63 506.71 2,849.28 3,345.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.11 0.32 0.26 0.20 0.53 0.00 0.00 0.01 0.05 0.03
Long-Term Debt to Equity		 0.00 0.00 0.19 0.26 0.16 0.27 0.00 0.00 0.01 0.05 0.03
Financial Leverage		 -1.16 -0.91 -1.06 -1.02 -1.00 -1.05 -1.08 -1.05 -1.06 -1.05 -1.04
Leverage Ratio		 -0.66 1.28 1.48 1.44 1.32 1.44 1.19 1.09 1.10 1.11 1.11
Compound Leverage Factor		 -0.76 1.30 1.51 1.46 1.36 1.47 1.19 1.08 1.06 1.03 1.00
Debt to Total Capital		 0.00% 9.60% 24.13% 20.49% 16.71% 34.52% 0.00% 0.00% 1.16% 4.37% 2.97%
Short-Term Debt to Total Capital		 0.00% 9.60% 9.92% 0.00% 3.72% 16.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 14.21% 20.49% 12.98% 17.99% 0.00% 0.00% 1.16% 4.37% 2.97%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 150.62% 71.30% 35.56% 44.68% 27.29%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 387.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 90.40% -312.04% 79.51% 83.29% 65.48% -50.62% 28.70% 63.28% 50.95% 69.74%
Debt to EBITDA		 0.00 -0.10 -0.29 -0.38 -0.31 -0.20 0.00 0.00 -0.03 -0.08 -0.07
Net Debt to EBITDA		 0.00 0.88 1.04 1.43 1.57 0.44 0.00 0.00 3.13 1.72 2.22
Long-Term Debt to EBITDA		 0.00 0.00 -0.17 -0.38 -0.24 -0.10 0.00 0.00 -0.03 -0.08 -0.07
Debt to NOPAT		 0.00 -0.14 -0.40 -0.53 -0.44 -0.28 0.00 0.00 -0.05 -0.11 -0.10
Net Debt to NOPAT		 0.00 1.24 1.46 2.02 2.25 0.63 0.00 0.00 4.47 2.57 3.33
Long-Term Debt to NOPAT		 0.00 0.00 -0.24 -0.53 -0.35 -0.15 0.00 0.00 -0.05 -0.11 -0.10
Altman Z-Score		 0.00 -1.84 -4.87 7.00 0.65 -10.80 -1.21 13.47 16.13 11.54 10.78
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 302.28% 143.71% 0.00% 0.00% 133.15% 102.24% 47.36% 41.65% 35.50%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.41 4.75 3.47 13.31 9.71 2.92 12.14 14.68 12.93 18.26 15.43
Quick Ratio		 3.12 4.55 3.21 12.55 9.28 2.64 11.96 14.44 12.73 17.93 14.99
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.61 -7.64 -8.95 -22 -21 -27 -72 -54 -78 -188 -199
Operating Cash Flow to CapEx		 -831.95% -5,608.13% -5,902.00% -11,450.00% -6,032.36% -42,923.81% -70,902.38% -21,073.75% -11,773.90% -20,508.91% -45,463.60%
Free Cash Flow to Firm to Interest Expense		 -3.53 -54.20 -27.45 -56.98 -24.43 -32.86 -142.62 -18,054.20 -161.36 -101.69 -65.37
Operating Cash Flow to Interest Expense		 -2.16 -48.92 -45.26 -73.54 -30.75 -43.18 -58.62 -18,193.67 -193.08 -99.71 -76.27
Operating Cash Flow Less CapEx to Interest Expense		 -2.42 -49.79 -46.03 -74.19 -31.26 -43.28 -58.70 -18,280.00 -194.72 -100.20 -76.44
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.73 0.24 0.18 0.10 0.14 0.09 0.01 0.02 0.01 0.00 0.00
Accounts Receivable Turnover		 4.15 3.43 16.80 5.42 11.33 0.00 0.00 0.00 0.00 3.08 0.00
Inventory Turnover		 12.56 13.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.03 2.14 3.91 6.74 13.00 7.14 2.52 8.66 2.08 0.21 0.21
Accounts Payable Turnover		 4.81 3.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 87.95 106.57 21.73 67.29 32.21 0.00 0.00 0.00 0.00 118.57 0.00
Days Inventory Outstanding (DIO)		 29.06 27.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 75.91 113.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 41.11 19.75 21.73 67.29 32.21 0.00 0.00 0.00 0.00 118.57 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.87 0.68 -2.26 0.99 -0.84 -2.79 -7.60 -9.25 -25 -15 -25
Invested Capital Turnover		 2.94 3.26 -4.41 -6.31 110.34 -2.46 -0.20 -0.35 -0.10 -0.02 -0.01
Increase / (Decrease) in Invested Capital		 -1.20 -0.19 -2.94 3.25 -1.83 -1.95 -4.82 -1.65 -16 9.70 -10
Enterprise Value (EV)		 0.00 -1.77 63 195 41 -3.29 117 366 898 895 1,010
Market Capitalization		 0.00 7.96 3.60 233 93 15 64 429 1,176 1,145 1,519
Book Value per Share		 $2.66 $0.98 ($5.74) $1.73 $1.66 $0.50 ($1.04) $2.48 $6.28 $4.48 $6.09
Tangible Book Value per Share		 $2.66 $0.98 ($5.74) $1.73 $1.66 $0.50 ($1.04) $2.48 $6.28 $4.48 $6.09
Total Capital		 5.99 12 20 48 62 24 120 188 400 462 692
Total Debt		 0.00 1.11 4.79 9.92 10 8.30 0.00 0.00 4.65 20 21
Total Long-Term Debt		 0.00 0.00 2.82 9.92 8.00 4.33 0.00 0.00 4.65 20 21
Net Debt		 -5.12 -9.73 -17 -38 -52 -19 -128 -197 -420 -457 -697
Capital Expenditures (CapEx)		 0.27 0.12 0.25 0.25 0.45 0.08 0.04 0.26 0.80 0.90 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.32 -0.46 -3.14 0.53 -1.55 -3.31 -8.70 -10 -27 -18 -27
Debt-free Net Working Capital (DFNWC)		 4.80 10 19 48 61 24 119 187 398 460 691
Net Working Capital (NWC)		 4.80 9.27 17 48 59 20 119 187 398 460 691
Net Nonoperating Expense (NNE)		 3.08 3.50 5.38 7.94 9.54 12 33 24 36 60 61
Net Nonoperating Obligations (NNO)		 -5.12 -9.73 -17 -38 -52 -19 -128 -197 -420 -457 -697
Total Depreciation and Amortization (D&A)		 0.14 0.18 0.30 0.30 -0.14 -0.14 0.58 1.17 0.27 -11 -15
Debt-free, Cash-free Net Working Capital to Revenue		 -7.48% -18.16% -90.39% 13.24% -18.48% -74.20% -828.76% -352.28% -1,508.24% -5,581.85% -8,939.40%
Debt-free Net Working Capital to Revenue		 111.02% 408.63% 545.33% 1,198.38% 726.58% 527.57% 11,327.33% 6,295.21% 22,450.56% 146,446.82% 228,671.19%
Net Working Capital to Revenue		 111.02% 365.09% 488.70% 1,198.38% 699.22% 438.44% 11,327.33% 6,295.21% 22,450.56% 146,446.82% 228,671.19%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($787.50) ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) ($6.66) ($4.05) ($5.31) ($412.71)
Adjusted Weighted Average Basic Shares Outstanding		 33.36K 47.60K 1.42M 2.01M 2.06M 3.54M 7.23M 11.92M 32.09M 44.76M 68.19M
Adjusted Diluted Earnings per Share		 ($787.50) ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) ($6.66) ($4.05) ($5.31) ($412.71)
Adjusted Weighted Average Diluted Shares Outstanding		 33.36K 47.60K 1.42M 2.01M 2.06M 3.54M 7.23M 11.92M 32.09M 44.76M 68.19M
Adjusted Basic & Diluted Earnings per Share		 ($787.50) ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.03K 35.96K 48.09K 1.28M 1.97M 2.09M 3.56M 25.91M 42.90M 62.77M 81.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.88 -7.83 -12 -19 -23 -29 -77 -56 -94 -178 -209
Normalized NOPAT Margin		 -112.89% -308.55% -341.99% -463.96% -276.16% -658.72% -7,358.67% -1,883.55% -5,305.46% -56,724.52% -69,312.75%
Pre Tax Income Margin		 -182.64% -446.34% -497.93% -672.37% -404.92% -959.74% -10,560.76% -2,680.16% -7,329.23% -75,711.47% -89,387.09%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.71 -79.34 -52.11 -69.27 -37.90 -50.27 -217.28 -26,576.00 -276.35 -137.76 -98.17
NOPAT to Interest Expense		 -4.70 -55.54 -36.48 -48.49 -26.53 -35.19 -152.10 -18,603.20 -193.44 -96.43 -68.72
EBIT Less CapEx to Interest Expense		 -6.97 -80.21 -52.87 -69.92 -38.41 -50.37 -217.37 -26,662.33 -277.99 -138.25 -98.34
NOPAT Less CapEx to Interest Expense		 -4.96 -56.41 -37.24 -49.13 -27.04 -35.29 -152.18 -18,689.53 -195.08 -96.92 -68.89
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -6.96% -9.29% -0.18% -5.58% -10.42% -16.99% -4.96% -9.98%

Quarterly Metrics and Ratios for Viridian Therapeutics

This table displays calculated financial ratios and metrics derived from Viridian Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 474.52% 68.69% -100.00% 0.00% -93.97% -52.91% 0.00% 0.00% 19.44% -15.29%
EBITDA Growth		 -112.55% -73.37% -194.39% -112.35% -81.61% -49.20% 19.92% -23.12% -61.85% -21.84%
EBIT Growth		 -110.73% -68.72% -179.94% -100.50% -71.98% -45.68% 22.87% -21.78% -62.97% -22.37%
NOPAT Growth		 -110.73% -68.72% -179.94% -100.50% -71.98% -45.68% 22.87% -21.78% -62.97% -22.37%
Net Income Growth		 -105.83% -58.17% -165.25% -86.71% -64.89% -46.03% 28.77% -18.03% -60.91% -19.24%
EPS Growth		 31.20% 41.56% -64.29% -19.81% -26.74% -36,613.38% 50.93% 19.69% -5.50% 21.40%
Operating Cash Flow Growth		 -74.03% -105.88% -194.52% -149.99% -88.62% -11.63% 27.03% -1.87% -73.68% -92.98%
Free Cash Flow Firm Growth		 -1,312.25% -0.24% -100.04% -159.73% -256.78% -218.50% -16.01% -0.44% 3.36% 14.60%
Invested Capital Growth		 -91.97% -168.58% -112.06% 6.78% 46.72% 39.04% 44.56% -57.21% -167.43% -67.49%
Revenue Q/Q Growth		 0.00% -69.79% -100.00% 0.00% 0.00% 136.11% 100.00% 0.00% 19.44% 67.44%
EBITDA Q/Q Growth		 -0.98% -68.85% -51.25% 17.65% 13.64% -38.72% 18.82% -26.60% -13.53% -4.43%
EBIT Q/Q Growth		 -0.75% -64.73% -47.71% 18.21% 13.58% -39.54% 21.80% -29.14% -15.64% -4.78%
NOPAT Q/Q Growth		 -0.75% -64.73% -47.71% 18.21% 13.58% -39.54% 21.80% -29.14% -15.64% -4.78%
Net Income Q/Q Growth		 1.99% -58.40% -48.85% 19.20% 13.44% -40.29% 27.40% -33.89% -18.00% -3.96%
EPS Q/Q Growth		 18.87% -65.12% -12.59% 21.12% 14.17% -47,728.44% 41.04% -29.11% -12.75% -35,530.43%
Operating Cash Flow Q/Q Growth		 -14.28% -64.71% -82.05% 27.04% 13.78% 2.52% -19.01% -1.85% -47.00% -8.31%
Free Cash Flow Firm Q/Q Growth		 24.40% -51.63% -118.01% -3.93% -3.85% -35.36% 20.59% 10.02% 0.08% -19.61%
Invested Capital Q/Q Growth		 -20.23% -40.33% 25.00% 26.34% 31.29% -60.57% 31.79% -108.90% -16.89% -0.56%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,467.03% -13,789.20% 0.00% -86,108.33% -74,362.50% -43,689.41% 0.00% -106,013.89% -100,761.63% -62,844.44%
Operating Margin		 -2,492.47% -13,591.69% 0.00% -82,326.39% -71,144.44% -42,045.88% 0.00% -100,259.72% -97,069.77% -60,743.75%
EBIT Margin		 -2,492.47% -13,591.69% 0.00% -82,326.39% -71,144.44% -42,045.88% 0.00% -100,259.72% -97,069.77% -60,743.75%
Profit (Net Income) Margin		 -2,418.83% -12,682.83% 0.00% -76,476.39% -66,194.44% -39,329.41% 0.00% -90,268.06% -89,173.26% -55,364.58%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.05% 93.31% 94.04% 92.89% 93.04% 93.54% 86.84% 90.03% 91.87% 91.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.84% -44.57% -66.64% -86.47% -62.57% -56.80% -46.75% -53.97% -51.88% -48.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -12.24% -75.41% 0.00% -514.22% -93.40% -28.53% 0.00% 0.00% -2.47% -29.76%
Return on Assets (ROA)		 -11.88% -70.36% 0.00% -477.68% -86.90% -26.69% 0.00% 0.00% -2.27% -27.12%
Return on Common Equity (ROCE)		 -18.61% -23.46% -34.81% -41.44% -37.54% -33.14% -29.99% -32.60% -34.93% -31.27%
Return on Equity Simple (ROE_SIMPLE)		 -27.64% 0.00% -49.16% -62.66% -76.40% 0.00% -37.44% -43.08% -36.34% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -34 -51 -41 -36 -50 -39 -51 -58 -61
NOPAT Margin		 -1,744.73% -9,514.18% 0.00% -57,628.47% -49,801.11% -29,432.12% 0.00% -70,181.81% -67,948.84% -42,520.63%
Net Nonoperating Expense Percent (NNEP)		 -2.52% -3.71% -6.40% -5.58% -3.28% -3.84% -1.96% -3.29% -3.56% -3.21%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.59% - - - -10.82% - - - -8.85%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 741.51% 2,729.64% 0.00% 26,755.56% 29,043.06% 19,407.65% 0.00% 22,313.89% 16,753.49% 10,822.22%
R&D to Revenue		 1,850.96% 10,891.14% 0.00% 55,670.83% 42,201.39% 22,680.59% 0.00% 78,045.83% 80,416.28% 49,971.53%
Operating Expenses to Revenue		 2,592.47% 13,620.78% 0.00% 82,426.39% 71,244.44% 42,088.24% 0.00% 100,359.72% 97,169.77% 60,793.75%
Earnings before Interest and Taxes (EBIT)		 -30 -49 -72 -59 -51 -71 -56 -72 -83 -87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -50 -75 -62 -54 -74 -60 -76 -87 -90
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.19 4.65 5.06 5.67 4.51 4.86 2.41 2.52 2.80 3.15
Price to Tangible Book Value (P/TBV)		 2.19 4.65 5.06 5.67 4.51 4.86 2.41 2.52 2.80 3.15
Price to Revenue (P/Rev)		 359.26 663.46 701.37 630.30 1,326.54 3,647.53 0.00 0.00 103,821.12 5,028.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 184.14 506.71 550.81 510.72 1,013.48 2,849.28 0.00 0.00 64,975.98 3,345.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.01 0.01 0.07 0.05 0.03 0.04 0.03 0.03
Long-Term Debt to Equity		 0.01 0.01 0.01 0.01 0.07 0.05 0.03 0.03 0.03 0.03
Financial Leverage		 -1.04 -1.06 -1.05 -1.06 -1.04 -1.05 -1.03 -1.04 -1.04 -1.04
Leverage Ratio		 1.08 1.10 1.10 1.14 1.11 1.11 1.09 1.11 1.11 1.11
Compound Leverage Factor		 1.05 1.02 1.04 1.06 1.03 1.03 0.95 1.00 1.02 1.01
Debt to Total Capital		 1.12% 1.16% 1.32% 1.47% 6.59% 4.37% 3.37% 3.72% 2.82% 2.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.54% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.12% 1.16% 1.32% 1.47% 6.59% 4.37% 3.37% 3.18% 2.82% 2.97%
Preferred Equity to Total Capital		 34.37% 35.56% 37.98% 42.09% 44.44% 44.68% 33.13% 36.32% 25.95% 27.29%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 64.52% 63.28% 60.70% 56.45% 48.97% 50.95% 63.50% 59.96% 71.24% 69.74%
Debt to EBITDA		 -0.04 -0.03 -0.03 -0.02 -0.08 -0.08 -0.08 -0.08 -0.07 -0.07
Net Debt to EBITDA		 3.78 3.13 2.01 1.52 1.22 1.72 2.37 2.08 2.46 2.22
Long-Term Debt to EBITDA		 -0.04 -0.03 -0.03 -0.02 -0.08 -0.08 -0.08 -0.07 -0.07 -0.07
Debt to NOPAT		 -0.06 -0.05 -0.04 -0.03 -0.12 -0.11 -0.12 -0.12 -0.10 -0.10
Net Debt to NOPAT		 5.33 4.47 2.92 2.24 1.80 2.57 3.56 3.14 3.70 3.33
Long-Term Debt to NOPAT		 -0.06 -0.05 -0.04 -0.03 -0.12 -0.11 -0.12 -0.10 -0.10 -0.10
Altman Z-Score		 10.59 16.78 16.61 15.39 6.67 12.77 10.68 7.55 12.65 11.73
Noncontrolling Interest Sharing Ratio		 49.48% 47.36% 47.76% 52.08% 40.00% 41.65% 35.86% 39.59% 32.67% 35.50%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.35 12.93 12.93 12.09 13.93 18.26 23.99 15.82 18.55 15.43
Quick Ratio		 17.12 12.73 12.64 11.67 13.47 17.93 23.47 15.54 18.21 14.99
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -19 -41 -42 -44 -60 -47 -43 -43 -51
Operating Cash Flow to CapEx		 -14,869.06% -18,204.28% -53,889.57% -13,659.82% -9,649.26% -79,166.67% 0.00% -44,286.54% -23,107.85% -64,326.32%
Free Cash Flow to Firm to Interest Expense		 -75.42 -111.63 -247.79 -255.97 -73.55 -65.21 -80.80 -71.49 -42.48 -59.45
Operating Cash Flow to Interest Expense		 -126.02 -202.63 -375.59 -272.37 -64.97 -41.48 -77.04 -77.15 -67.44 -85.47
Operating Cash Flow Less CapEx to Interest Expense		 -126.87 -203.74 -376.29 -274.37 -65.65 -41.54 -77.04 -77.32 -67.73 -85.60
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.71 0.00 4.79 4.10 2.02 3.08 0.00 0.00 0.24 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.77 2.08 1.36 1.24 0.38 0.21 0.00 0.00 0.01 0.21
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 98.49 0.00 76.24 89.12 180.69 118.57 0.00 0.00 1,512.14 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 98.49 0.00 76.24 89.12 180.69 118.57 0.00 0.00 1,512.14 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -18 -25 -19 -14 -9.43 -15 -10 -22 -25 -25
Invested Capital Turnover		 -0.12 -0.10 -0.11 -0.11 -0.04 -0.02 0.00 0.00 0.00 -0.01
Increase / (Decrease) in Invested Capital		 -8.48 -16 -9.85 1.00 8.27 9.70 8.30 -7.85 -16 -10
Enterprise Value (EV)		 299 898 857 831 512 895 528 479 910 1,010
Market Capitalization		 584 1,176 1,091 1,026 670 1,145 921 830 1,453 1,519
Book Value per Share		 $9.38 $6.28 $5.03 $4.20 $3.40 $4.48 $6.27 $5.16 $8.12 $6.09
Tangible Book Value per Share		 $9.38 $6.28 $5.03 $4.20 $3.40 $4.48 $6.27 $5.16 $8.12 $6.09
Total Capital		 414 400 355 321 304 462 603 550 728 692
Total Debt		 4.61 4.65 4.68 4.71 20 20 20 20 21 21
Total Long-Term Debt		 4.61 4.65 4.68 4.71 20 20 20 17 21 21
Net Debt		 -427 -420 -369 -330 -293 -457 -593 -551 -733 -697
Capital Expenditures (CapEx)		 0.14 0.19 0.12 0.33 0.40 0.05 0.00 0.10 0.29 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -27 -21 -17 -12 -18 -12 -24 -27 -27
Debt-free Net Working Capital (DFNWC)		 412 398 353 318 301 460 601 548 726 691
Net Working Capital (NWC)		 412 398 353 318 301 460 601 545 726 691
Net Nonoperating Expense (NNE)		 8.06 11 17 14 12 17 9.41 14 18 18
Net Nonoperating Obligations (NNO)		 -427 -420 -369 -330 -293 -457 -593 -551 -733 -697
Total Depreciation and Amortization (D&A)		 0.30 -0.71 -2.82 -2.72 -2.32 -2.79 -4.40 -4.14 -3.18 -3.03
Debt-free, Cash-free Net Working Capital to Revenue		 -1,180.37% -1,508.24% -1,339.59% -1,020.70% -2,458.42% -5,581.85% 0.00% 0.00% -194,621.43% -8,939.40%
Debt-free Net Working Capital to Revenue		 25,362.52% 22,450.56% 22,687.28% 19,513.15% 59,523.17% 146,446.82% 0.00% 0.00% 5,185,664.29% 228,671.19%
Net Working Capital to Revenue		 25,362.52% 22,450.56% 22,687.28% 19,513.15% 59,523.17% 146,446.82% 0.00% 0.00% 5,185,664.29% 228,671.19%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.86) ($1.42) ($1.61) ($1.27) ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75)
Adjusted Weighted Average Basic Shares Outstanding		 33.74M 32.32M 42.24M 43.25M 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M
Adjusted Diluted Earnings per Share		 ($0.86) ($1.42) ($1.61) ($1.27) ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75)
Adjusted Weighted Average Diluted Shares Outstanding		 33.74M 32.32M 42.24M 43.25M 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.42) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.25M 42.90M 43.13M 43.67M 52.59M 62.77M 63.82M 63.89M 79.21M 81.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -34 -51 -41 -36 -50 -39 -51 -58 -61
Normalized NOPAT Margin		 -1,744.73% -9,514.18% 0.00% -57,628.47% -49,801.11% -29,432.12% 0.00% -70,181.81% -67,948.84% -42,520.63%
Pre Tax Income Margin		 -2,418.83% -12,682.83% 0.00% -76,476.39% -66,194.44% -39,329.41% 0.00% -90,268.06% -89,173.26% -55,364.58%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -181.62 -292.06 -439.23 -357.08 -85.37 -78.03 -95.22 -120.92 -83.15 -101.95
NOPAT to Interest Expense		 -127.13 -204.44 -307.46 -249.95 -59.76 -54.62 -66.66 -84.64 -58.20 -71.36
EBIT Less CapEx to Interest Expense		 -182.46 -293.17 -439.93 -359.07 -86.05 -78.09 -95.22 -121.09 -83.44 -102.08
NOPAT Less CapEx to Interest Expense		 -127.98 -205.55 -308.16 -251.95 -60.43 -54.68 -66.66 -84.82 -58.50 -71.50
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -20.38% -16.99% 0.00% 0.00% -0.43% -4.96% -10.17% -9.77% -14.56% -9.98%

Frequently Asked Questions About Viridian Therapeutics' Financials

When does Viridian Therapeutics's financial year end?

According to the most recent income statement we have on file, Viridian Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Viridian Therapeutics' net income changed over the last 10 years?

Viridian Therapeutics' net income appears to be on an upward trend, with a most recent value of -$269.95 million in 2024, rising from -$7.89 million in 2014. The previous period was -$237.73 million in 2023.

What is Viridian Therapeutics's operating income?
Viridian Therapeutics's total operating income in 2024 was -$299.04 million, based on the following breakdown:
  • Total Gross Profit: $302 thousand
  • Total Operating Expenses: $299.34 million
How has Viridian Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Viridian Therapeutics' total revenue changed from $4.32 million in 2014 to $302 thousand in 2024, a change of -93.0%.

How much debt does Viridian Therapeutics have?

Viridian Therapeutics' total liabilities were at $70.76 million at the end of 2024, a 46.2% increase from 2023, and a 3,272.9% increase since 2014.

How much cash does Viridian Therapeutics have?

In the past 10 years, Viridian Therapeutics' cash and equivalents has ranged from $5.12 million in 2014 to $155.58 million in 2022, and is currently $99.59 million as of their latest financial filing in 2024.

How has Viridian Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Viridian Therapeutics' book value per share changed from 2.66 in 2014 to 6.09 in 2024, a change of 129.5%.

Remove Ads

Related Companies

This page (NASDAQ:VRDN) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...
Crypto 101 Media | Sponsored
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
First look: The $3,500 iPhone
Did you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...
Stansberry Research | Sponsored